Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03694626 · ClinicalTrials.gov registry record · NA

Objectively Diagnose and Monitor Treatment of Light Sensitivity

A NA study of Traumatic Brain Injury and Migraine, sponsored by Randy Kardon.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT03694626 is a NA study of Traumatic Brain Injury and Migraine that is actively recruiting participants, run by Randy Kardon. The registered enrollment target is 120 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03694626, a NA study of Traumatic Brain Injury and Migraine, is actively recruiting participants, sponsored by Randy Kardon.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to provide a new framework for diagnosing and monitoring treatment of light sensitivity and headache by objective measurement of facial features, pupil responses, retinal electrical responses and autonomic nerve responses to light.

Interventions

  • DEVICE Pupillography
  • DEVICE Ocular Coherence Tomography (OCT)
  • DEVICE Wrist-watch sensor device
  • DEVICE Videography
  • DEVICE Electrophysiology

Study Locations (1)

Iowa

  • University of Iowa Health Care - Iowa City

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2019-07-11
Est. Completion 2028-01-01
Phase NA

Sponsor

Randy Kardon

4 total trials

What the Registry Record Tells You About NCT03694626

The ClinicalTrials.gov registry entry for NCT03694626 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (57% lower). The listed sponsor is Randy Kardon, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Traumatic Brain Injury appearing as the primary indexed condition, and to 5 interventions - of which Pupillography is the first listed.

NCT03694626 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.

Frequently Asked Questions

What is clinical trial NCT03694626 about?

NCT03694626 is a clinical study titled "Objectively Diagnose and Monitor Treatment of Light Sensitivity". The purpose of this project is to provide a new framework for diagnosing and monitoring treatment of light sensitivity and headache by objective measurement of facial features, pupil responses, retinal electrical responses and autonomic nerve responses to light.

What is the current status of trial NCT03694626?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2019-07-11. Estimated completion is 2028-01-01.

What conditions does trial NCT03694626 study?

This clinical trial studies the following conditions: Traumatic Brain Injury, Migraine, Photophobia.

What interventions are being tested in trial NCT03694626?

The interventions under investigation include: Pupillography (DEVICE), Ocular Coherence Tomography (OCT) (DEVICE), Wrist-watch sensor device (DEVICE), Videography (DEVICE), Electrophysiology (DEVICE).

Who is sponsoring clinical trial NCT03694626?

This trial is sponsored by Randy Kardon, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03694626 being conducted?

This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Traumatic Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.